Ben Bronstein, M.D.

Dr. Bronstein joined the Aldeyra board of directors in 2010, and is an independent consultant to companies in the life science industry. Prior to his consulting role, he was Executive Vice President, Clinical Development of Aclaris Therapeutics, Inc. Dr. Bronstein has more than 30 years of entrepreneurial and leadership experience across the life science and venture capital industries. He founded or held senior management roles at companies including Neuron Systems, Inc. (the predecessor to Aldeyra Therapeutics, Inc.), BioSurface Technology, Inc., Peptimmune, Inc., OPKO Health, Inc., and Vidus Ocular, Inc. In addition, he was Chief Medical Officer for Stealth BioTherapeutics, Inc., a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School and a founder and Senior Vice President of Access BridgeGap Ventures. A board-certified pathologist with more than 20 publications, Dr. Bronstein began his professional career on the staff of Massachusetts General Hospital and on the faculty of Harvard Medical School. He serves as a board member for several privately held life science companies. Dr. Bronstein received his M.D. and M.B.A. from Boston University.